Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct;26(10):e1893-e1894.
doi: 10.1002/onco.13884. Epub 2021 Jul 10.

Limited Impact of HER2 Expression on Survival Outcomes in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection

Yutaro Hori  1 , Tomoaki Yoh  1 , Satoru Seo  1 , Sachiko Minamiguchi  2 , Hironori Haga  2 , Kojiro Taura  1
Affiliations
Comment

Limited Impact of HER2 Expression on Survival Outcomes in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection

Yutaro Hori et al. Oncologist. 2021 Oct.

Abstract

This letter to the editor remarks on the topic of HER2 expression as a potential target of adjuvant therapy for biliary tract cancer, focusing on patients with intrahepatic cholangiocarcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Examples of HER2 immunohistochemistry (IHC) staining. (A): Score 1+. (B): Score 0. Of the 51 samples, two samples had score 1, and 49 samples had score 0. IHC in HER2 was performed using rabbit anti‐ErbB2 antibody (ab214275, Abcam plc, Cambridge, U.K.) at 1:400 dilutions, and staining was done with an automated staining machine (Ventana Discovery Ultra, Roche Diagnostics, Tokyo, Japan).
See this image and copyright information in PMC

Comment in

  • In Reply.
    Salani F, Ugolini C, Catanese S, Cacciato Insilla A, Fornaro L, Campani D, Vasile E, Fontanini G, Masi G, Vivaldi C. Salani F, et al. Oncologist. 2021 Oct;26(10):e1895-e1896. doi: 10.1002/onco.13886. Epub 2021 Jul 17. Oncologist. 2021. PMID: 34176190 Free PMC article.

Comment on

References

    1. Vivaldi C, Fornaro L, Ugolini C et al. HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer. The Oncologist 2020;25:886–893. - PMC - PubMed
    1. Nakamura H, Arai Y, Totoki Y et al. Genomic spectra of biliary tract cancer. Nat Genet 2015;47:1003–1010. - PubMed
    1. Galdy S, Lamerca A, McNamara MG et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta‐analysis: A potential therapeutic target? Cancer Metastasis Rev 2017;36:141–157. - PMC - PubMed
    1. Hoffmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 2008;52:797–805. - PubMed
    1. Roos E, Strijiker M, Franken LC et al. Comparison of short‐ and long‐term outcomes between anatomical subtypes of resected biliary tract cancer in a Western high‐volume center. HPB (Oxford) 2020;22:405–414. - PubMed